Broker Forecast - HSBC issues a broker note on GlaxoSmithKline PLC

Writer, Stock Market Wire
Thursday, February 7, 2019 - 10:50

HSBC today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1860p (from 1820p).

Broker Forecasts data provided by www.sharesmagazine.co.uk


Related content

FTSE 100 down to five female CEOs as Laury prepares to leave Kingfisher

When Kingfisher boss Véronique Laury steps down on 25 September she will become the tenth FTSE 100 CEO to do so this year, with...

Wed, 18/09/2019 - 10:43


Broker Forecast - Deutsche Bank issues a broker note on GlaxoSmithKline PLC

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1645p (from 1620p).

Broker Forecasts data provided...

Mon, 02/09/2019 - 08:50


Temple Bar could outperform if markets turn sour

Author: 

Investors seeking a portfolio of cheap, dividend-paying stocks and selling on a 6.3% discount to net asset value (NAV) should look to Temple Bar Investment...

Thu, 29/08/2019 - 00:00


GlaxoSmithKline blood cancer treatment meets primary objective in clinical trial

GlaxoSmithKline said a clinical study of its blood cancer treatment had met its primary goal.

'The two-arm study met its primary objective and demonstrated...

Fri, 23/08/2019 - 07:16


GlaxoSmithKline's JV ViiV Healthcare says trial of injectable HIV treatment met objectives

ViiV Healthcare, a GlaxoSmithKline-Pfizer joint venture, said its injectable HIV treatment had met its primary goal in a clinical trial, reducing the number of treatments...

Thu, 22/08/2019 - 07:41